Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2052291 | 0.83 | NPC1 (0.50) | THRBMAPTPTGDR2FSCN1BRD4 | |
| SCHEMBL12643368 | 0.77 | PTGDR2 (0.40) | MAPTPTGDR2FSCN1HPGDBRD4 | |
| SCHEMBL2038326 | 0.77 | PTGDR2 (0.40) | MAPTPTGDR2FSCN1HPGDBRD4 | |
| SCHEMBL13585256 | 0.74 | BRD4 (0.41) | MAPTPTGDR2FSCN1BRD4L3MBTL1 | |
| SCHEMBL12643367 | 0.74 | BRD4 (0.41) | MAPTPTGDR2FSCN1BRD4L3MBTL1 | |
| SCHEMBL25692948 | 0.71 | IDO1 (0.48) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2049892 | 0.66 | DAO (0.40) | MAPT | |
| SCHEMBL3362041 | 0.66 | ALOX5 (0.50) | HPGDSMN1; SMN2KDM4E | |
| SCHEMBL13584040 | 0.66 | BRD4 (0.41) | THRBMAPTPTGDR2HPGDBRD4 | |
| SCHEMBL2035315 | 0.66 | BRD4 (0.41) | THRBMAPTPTGDR2HPGDBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102753526-B | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIV GEORGIA | 2014-11-26 | — | — | CN | disclosed |
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | disclosed |
| EP-2509949-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | University Of Georgia Research Foundation, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071849-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071849-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | PAICS, DUT, AADAC | THRB 3428/4885MAPT 585/4885PTGDR2 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.